Occuity

Occuity seeks to develop revolutionary non-invasive screening and monitoring devices for chronic diseases like diabetes and Alzheimer's. It argues that its device safely shines a low power beam of light into the eye and then collects and analyses the return signal to accurately measure structures within the eye and detect changes associated with the onset of the aforementioned diseases. Occuity is targeting three distinct markets, namely Ophthalmology, Disease Screening and Disease Monitoring, which is worth an estimated $35 billion per year. It claims that its 'Occuity Indigo' product enables earlier detection of diabetes and provides a non-contacting, pain-free glucose monitor. Occuity was awarded over £1.5 million as part of the Innovate UK grant for the development of technology within Occuity Indigo. It has also signed a partnership with one of the UK's leading ophthalmic distributors, Birmingham Optical, to distribute its PM1 pachymeter device. It states it will use 42% of the investment towards Research and Development (R&D), 23% towards sales and marketing, 20% towards management and finance, 9% towards managing CAPEX and NRE, and 6% towards paying fees.